Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa study of BST204 for cancer-related cachexia in gastrointestinal or non-small-cell lung cancer
2017-003271-61Phase 2Completed
- Sponsor
- GC Wellbeing
- Start
- Oct 2017
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of BST204 in cancer anorexia-cachexia syndrome (CACS), sponsored by GC Wellbeing. Started Oct 2017; status: completed.
02
Drugs
BST204
03
Conditions
cancer anorexia-cachexia syndrome (CACS)
Beyond the preview
Go deeper on 2017-003271-61.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003271-61.